Business Context and Reporting Period
This Form 8-K was filed by Accuray Incorporated on March 15, 2013. The report discloses a corporate governance event: the appointment of a new independent director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and compensation arrangements.
Material Changes
The Board of Directors increased the number of directors from 7 to 8. Dr. Emad Rizk was appointed as a Class III member of the Board, effective March 15, 2013. He is expected to stand for re-election at the 2015 annual meeting of stockholders.
Management Commentary and Compensation
Dr. Rizk, currently President of McKesson Health Solutions, will receive compensation consistent with other non-employee Board members:
- Cash Compensation: An annual retainer of $35,000 for Board service. Additional fees apply for committee service: $10,000 for the Audit Committee, $5,000 for the Compensation Committee, and $3,000 for the Nominating and Corporate Governance Committee. Per-meeting fees of $1,000 (in-person) or $500 (telephonic) apply for meetings exceeding the standard allotment.
- Equity Compensation: An initial Restricted Stock Unit (RSU) grant valued at $120,000 (prorated for the partial term) and an annual RSU grant valued at $120,000. All RSUs vest fully upon a change in control.
The filing states there are no related party transactions or special arrangements between Dr. Rizk and Accuray.
Investor Verification Checklist
- Verify the exact number of shares issued for the initial RSU grant based on the fair market value on the grant date.
- Confirm the specific Board committees, if any, to which Dr. Rizk is subsequently appointed.
- Review the company's proxy statement for the 2015 annual meeting to confirm Dr. Rizk's re-election status.